On April 2, 2026, the EPA placed pharmaceuticals on its draft Sixth Contaminant Candidate List (CCL 6) for the first time and simultaneously released human health benchmarks for 374 individual pharmaceutical compounds. That dual move did not create an enforceable standard — there is still no federal Maximum Contaminant Level (MCL) for any drug residue in drinking water — but it formally acknowledged a problem that researchers have documented for two decades: medications, in trace amounts, are routinely detected in finished US tap water. This profile explains which drugs reach the tap, how they get there, what the health evidence shows, and which treatment methods actually remove them.
What Are Pharmaceutical Contaminants?
Pharmaceutical contaminants are residues of human and veterinary medications — and their metabolites — that persist in water after passing through the human body, livestock, or wastewater systems. They are an unusually broad chemical category. Unlike a single contaminant such as lead or arsenic, “pharmaceuticals in water” encompasses thousands of distinct compounds with different chemical structures, environmental behaviors, and health profiles. The CCL 6 entry treats them as a group, the same structural shift the EPA used to elevate microplastics from individual-chemical listings to a category-level concern.
Detection levels are typically measured in nanograms per liter (ng/L) — parts per trillion. That is roughly one thousand times below the part-per-billion concentrations at which contaminants like nitrate or PFOA become regulatory issues. The trace-level reality cuts two ways. The exposures are small relative to a therapeutic dose, but they are continuous, involuntary, and span the entire population — including infants, pregnant people, and people taking other medications who may interact with low-dose exposures differently than the original drug trials accounted for.
The most commonly detected classes in US tap water include:
- Antidepressants and psychiatric medications — fluoxetine (Prozac), sertraline (Zoloft), citalopram, venlafaxine, carbamazepine
- Antibiotics — sulfamethoxazole, trimethoprim, ciprofloxacin, erythromycin
- Hormones — synthetic estrogens (ethinylestradiol), natural estrogens (estrone, estradiol), and androgens
- Painkillers and anti-inflammatories — ibuprofen, naproxen, acetaminophen, diclofenac
- Cardiovascular drugs — atenolol, metoprolol, gemfibrozil, statins
- Anticonvulsants — carbamazepine and primidone, both notably persistent and difficult to remove
- Veterinary antibiotics and growth promoters — primarily from concentrated animal feeding operations
Pharmaceutical residues are not detectable by taste, smell, or sight at the concentrations typically found in drinking water. Detection requires liquid chromatography mass spectrometry (LC-MS/MS) — instrumentation found in regulatory and academic labs, not in standard utility compliance monitoring.
How Pharmaceuticals Get Into Drinking Water
Drug residues reach the tap through three principal pathways. None of them are point-source spills, which is part of what makes pharmaceutical contamination structurally similar to microplastics — diffuse, continental in scale, and not solvable by shutting off a single discharge.
Human Excretion (the Dominant Source)
Most ingested medication is not fully absorbed or fully metabolized. The body excretes between 30% and 90% of an oral dose into urine and feces, either as the original parent compound or as metabolites that retain biological activity. Those excretions enter sewer systems and arrive at municipal wastewater treatment plants (WWTPs) at predictable, population-scaled concentrations. Cities with high prescribing rates of a given drug class show correspondingly higher concentrations in influent, and a 2020 USGS analysis found measurable diurnal and weekly cycles tied to dosing schedules — direct evidence that the source is the population taking the medication, not industrial discharge.
Wastewater Treatment Plant Limitations
Conventional WWTPs were not designed to remove pharmaceutical compounds. Activated sludge processes, primary clarification, and disinfection target nutrients, suspended solids, and pathogens. Many drug compounds — particularly carbamazepine, primidone, sulfamethoxazole, gemfibrozil, and contrast agents — pass through largely untreated, with removal rates often below 30%. Other compounds (ibuprofen, acetaminophen) are degraded efficiently. The net result is that WWTP effluent reliably carries a complex mixture of dozens of drug residues into receiving rivers, lakes, and coastal waters that downstream cities then withdraw for drinking water supply.
Improper Disposal and Veterinary Sources
Flushing unused medications down the toilet adds directly to the wastewater stream. The FDA maintains a “flush list” of drugs (mostly opioids and certain hormones) for which flushing is recommended over household disposal — a deliberate trade-off in which immediate diversion risk is judged to outweigh the marginal water-quality contribution from a single household. The greater contribution comes from routine disposal of antibiotics, hormones, and over-the-counter analgesics that should be handled through pharmacy take-back programs or mixed with kitty litter and discarded in the trash.
Veterinary medication is a parallel input. Concentrated animal feeding operations (CAFOs) discharge antibiotic residues, hormones, and veterinary drugs into surface and groundwater through manure runoff, lagoon seepage, and land application of biosolids. In agricultural regions, livestock-derived antibiotics are detectable in surface water at concentrations comparable to or exceeding human-derived loads.
Drinking Water Treatment Limitations
Drinking water plants drawing from rivers and lakes downstream of WWTPs face the residual mixture as raw influent. Conventional drinking water treatment — coagulation, flocculation, sedimentation, sand filtration, and chlorine or chloramine disinfection — removes some pharmaceuticals partially but leaves many in finished water at low ng/L concentrations. A 2008 Associated Press investigation that first brought national attention to pharmaceutical contamination found drug residues in the drinking water of 24 major US metropolitan areas serving over 41 million people; subsequent USGS and academic monitoring has confirmed that the basic finding — pharmaceuticals are present in finished US tap water — is now beyond reasonable dispute.
Health Effects
The health evidence for low-level pharmaceutical exposure through drinking water is genuinely uncertain, and that uncertainty is itself the regulatory crux. The EPA’s April 2026 release of human health benchmarks for 374 individual compounds gives utilities and states reference values for risk assessment, but the agency has not concluded that detected concentrations exceed those benchmarks at most US water systems.
What the EPA Benchmarks Mean
A health benchmark is a screening value — a concentration below which lifetime exposure is not expected to cause adverse effects, calculated using established toxicology methods and substantial safety factors. EPA’s 2026 benchmarks were derived using the same framework the agency uses for unregulated contaminant assessments: identification of the most sensitive toxicological endpoint for each drug, application of uncertainty factors for interspecies and intraspecies variation, and assumption of lifetime daily exposure at typical drinking water consumption rates. For most drugs evaluated, the benchmark values sit thousands of times higher than typical environmental detection levels — meaning that under standard toxicological assumptions, a single compound in isolation does not cross the screening threshold.
That conclusion comes with three important caveats.
The Mixture Problem
People are not exposed to a single pharmaceutical compound in drinking water. They are exposed to dozens simultaneously, often with overlapping mechanisms of action — multiple SSRIs, multiple beta-blockers, multiple synthetic hormones. Standard risk assessment evaluates compounds individually. The mixture problem is well-documented for disinfection byproducts and increasingly recognized for endocrine-disrupting chemicals, where additive or synergistic effects can produce adverse outcomes at concentrations where each component alone would be considered safe. The EPA acknowledges this gap; it is one of the explicit research priorities flagged in the CCL 6 supporting documentation.
Endocrine Disruption
Hormonal pharmaceuticals are biologically active at far lower concentrations than most drug classes. Synthetic estrogens, in particular, exhibit measurable biological effects on aquatic organisms at single-digit ng/L concentrations — a finding established in fish-feminization studies that prompted the original wave of pharmaceutical-in-water research in Europe two decades ago. Whether comparable effects occur in humans at drinking water exposure levels remains contested. The conservative reading of the literature is that hormones warrant more aggressive screening than the average drug compound, and the EPA’s prior CCL listings of estrogens (estrone, ethinylestradiol, equilin) reflect that.
Antibiotic Resistance
Trace antibiotic exposure does not cause acute toxicity, but it contributes to environmental antibiotic resistance — selection pressure on bacterial populations in surface water, sediment, and treated effluent that maintains and amplifies resistance genes. Resistance genes can transfer to human pathogens. The CDC has identified antimicrobial resistance as one of the largest public health threats of the coming decades. Drinking water is a smaller contributor than agricultural antibiotic use or hospital wastewater, but it is not zero.
Vulnerable Populations
Pregnant women, infants, and immunocompromised individuals face theoretical higher risk from low-dose pharmaceutical exposure. Fetal development is sensitive to hormonal disruption at concentrations well below adult thresholds, and infants consume substantially more water per kilogram of body weight than adults — roughly 4× more in the first six months of life. People taking medications themselves may face drug-drug interaction risk from background environmental exposure to compounds that share metabolic pathways or receptor activity, although the clinical significance of such interactions at typical detection levels is not well-characterized.
EPA Regulation and Limits
There is no federal Maximum Contaminant Level for any pharmaceutical compound in drinking water. The April 2026 CCL 6 listing is a research and monitoring designation, not an enforceable standard. The agency’s prior approach — listing individual hormones and a few specific drugs across CCL 1 through CCL 5 — has been replaced with a broader group-level designation that anticipates regulating pharmaceuticals as a class, similar to the trajectory PFAS followed.
| Standard | Value | Notes |
|---|---|---|
| EPA MCL (enforceable limit) | None | No federal drinking water standard exists |
| EPA MCLG (health goal) | None | Not yet established |
| Health benchmarks (374 drugs, 2026) | Compound-specific | Screening values, not enforceable |
| CCL 6 status | Listed (April 2026) | Research and monitoring priority |
| Public comment deadline | June 5, 2026 | Federal Register docket EPA-HQ-OW-2024-0581 |
| Final CCL 6 expected | November 17, 2026 | After Science Advisory Board review |
| State drinking water standards | None | A handful of states publish guidance values |
The regulatory trajectory matters because the CCL is the front end of a long pipeline. Listing on the CCL is required before the EPA can issue a regulatory determination, which is required before the agency can propose an MCL. PFAS, the only contaminant class to traverse that full pipeline through to enforceable limits in recent decades, took 26 years from its first CCL listing in 1998 to its final MCLs in April 2024. Pharmaceuticals are at year zero of that trajectory. A meaningful additional barrier: the EPA has not yet selected pharmaceutical classes for inclusion in the next Unregulated Contaminant Monitoring Rule (UCMR 6), and without nationwide monitoring data, the agency cannot make a positive regulatory determination.
The regulatory determinations published just two weeks before CCL 6 illustrate how cautious the EPA is about advancing CCL contaminants to enforceable limits. The CCL 5 determinations declined to regulate all nine contaminants evaluated, including microcystins and cylindrospermopsin — substances with substantially clearer dose-response data than most pharmaceuticals.
For the broader regulatory context, see our news coverage of the CCL 6 announcement and our CCL 6 explained guide, which walks through how a contaminant moves from CCL listing to enforceable MCL.
How Widespread Are Pharmaceuticals in US Drinking Water?
Pharmaceutical residues are nearly universal in finished US drinking water at trace levels, but concentrations vary by orders of magnitude based on source water and treatment.
The 2008 AP investigation identified at least one pharmaceutical compound in the drinking water supplies of 24 major metropolitan areas serving 41 million people. Subsequent USGS National Reconnaissance studies have detected pharmaceuticals in surface waters across all 50 states; a 2017 USGS sampling of 38 streams and rivers found pharmaceuticals in 91% of samples. Finished drinking water concentrations are substantially lower than influent — treatment removes a meaningful fraction — but the prevalence of detection is high.
Geographic factors that drive elevated concentrations:
- Downstream of large urban areas with discharging WWTPs. Cities drawing surface water from rivers that receive treated effluent upstream face higher influent loads. The Mississippi, Ohio, Potomac, Hudson, and lower Colorado all carry detectable pharmaceutical loads to downstream utilities.
- Agricultural regions with intensive livestock operations. Veterinary antibiotic and hormone residues elevate detections in surface and shallow groundwater. The Upper Midwest and Central Valley of California are notable hotspots.
- Coastal areas with mixing of WWTP outfalls and drinking water intakes. A subset of coastal cities draw drinking water from estuaries or wells subject to wastewater influence.
Private well users face a different and underappreciated risk profile. Wells located near septic systems, CAFOs, or land-applied biosolids can show pharmaceutical detections at concentrations exceeding those typical of treated municipal water. See our well water testing guide for what to test for and how often.
Population-scale exposure is essentially universal among people drinking US tap water. The questions that remain unresolved are which specific compounds matter, at what concentrations, and through which mechanisms — exactly the questions CCL 6 is designed to advance.
How WaterVerge Tracks Pharmaceuticals
WaterVerge city pages emphasize EPA-regulated contaminants — the substances utilities are legally required to monitor and report. Pharmaceuticals are not federally regulated, so they do not appear on Consumer Confidence Reports (CCRs) and are not part of the EPA’s Safe Drinking Water Information System (SDWIS) violation data that powers most of our utility-level grading.
We track pharmaceutical contamination at the policy and research level: the CCL 6 listing, EPA health benchmark releases, UCMR cycle inclusion decisions, and significant academic or USGS monitoring studies. As individual compounds advance toward formal regulation — most likely beginning with synthetic hormones or persistent compounds like carbamazepine — we will integrate their data into city-level pages. For now, the absence of a federal monitoring framework means there is no national dataset comparable to UCMR 5 PFAS results. Independent testing through certified labs is the only way to obtain pharmaceutical data for a specific tap.
How to Remove Pharmaceuticals
Pharmaceutical removal is one of the better-documented filtration use cases — both because the compounds have been studied extensively and because the household technologies that work also work for many other emerging contaminants. The single most important point: boiling does not remove pharmaceuticals. It concentrates them as water evaporates.
| Method | Removal Rate | Certification | Best For |
|---|---|---|---|
| Reverse osmosis (under-sink) | 90—99% (most compounds) | NSF/ANSI 58, NSF/ANSI 401 | Comprehensive removal, primary recommendation |
| Granular activated carbon (GAC) | 50—90% (compound-dependent) | NSF/ANSI 401 | Mid-tier removal at lower cost |
| NSF 401-certified pitcher/faucet filter | 85%+ on 15 listed pharma compounds | NSF/ANSI 401 | Renters, no installation |
| Ultrafiltration alone | Limited (size-dependent) | N/A for pharma | Not recommended as primary method |
| Standard activated carbon (uncertified) | Unreliable | None | Not recommended for pharmaceuticals |
| Boiling | Concentrates rather than removes | N/A | Do not rely on |
| Water softeners | Not effective | N/A | Wrong tool |
Reverse osmosis is the most reliable household method. RO membranes physically exclude molecules above roughly 100 daltons, which captures the vast majority of pharmaceutical compounds, and the activated carbon prefilters and postfilters in standard RO systems remove additional compounds that the membrane alone might pass. Look for NSF/ANSI 58 certification (the core RO standard) plus NSF/ANSI 401, the standard specifically developed to certify reduction of 15 emerging contaminants including ibuprofen, naproxen, estrone, atenolol, carbamazepine, and trimethoprim. See our guide to the best reverse osmosis systems for current certified options.
Granular activated carbon (GAC) systems — including most quality under-sink filters, whole-house filters, and a subset of pitcher and faucet-mount filters — remove pharmaceuticals at rates that depend on the compound’s hydrophobicity, the carbon’s surface area and contact time, and the filter’s age. Hydrophobic compounds (most painkillers, many psychiatric medications) are removed efficiently. Hydrophilic and persistent compounds (carbamazepine, sulfamethoxazole, primidone) are removed less reliably. NSF/ANSI 401 certification is the practical signal that a filter has been third-party tested against representative pharmaceutical compounds. Our guide to the best water filter pitchers flags pitcher options that carry NSF 401 certification.
What does not work: Standard activated carbon filters not certified to NSF 401 — including most refrigerator filters and many basic pitcher brands — provide unreliable pharmaceutical removal. Ultraviolet (UV) disinfection does not remove pharmaceuticals (UV is for pathogens, not chemicals). Reverse osmosis without an NSF 401 carbon stage performs well for most compounds but will not be third-party-validated against the same comparison matrix as NSF 401 systems.
One operational tip: Replace filter cartridges on schedule. Carbon filters lose capacity gradually, and a saturated carbon bed can release adsorbed compounds back into water. Saturation is the most common failure mode for pharmaceutical removal in household systems.
Frequently Asked Questions
Are pharmaceuticals in tap water at dangerous levels?
EPA and most independent toxicologists conclude that single-compound exposures in finished US drinking water are typically far below health-screening thresholds. The genuine uncertainty involves long-term mixture exposure, endocrine-disrupting hormones, and vulnerable populations. If you want to minimize exposure, an NSF/ANSI 401 certified filter is the most direct intervention.
Does boiling water remove pharmaceuticals?
No. Boiling does not remove pharmaceutical residues and may slightly concentrate them as water evaporates. Boiling addresses microbiological contamination, not chemical contamination. Use filtration certified to NSF/ANSI 401 instead.
Can I test my tap water for pharmaceuticals at home?
Not reliably. Pharmaceutical detection requires liquid chromatography mass spectrometry, which is laboratory equipment costing tens of thousands of dollars. A handful of certified labs offer pharmaceutical screening panels for $250–$600, typically covering 15–50 of the most commonly detected compounds. See our guide to testing your tap water for finding certified labs.
What’s the difference between this and microplastics?
Both were placed on CCL 6 in April 2026, both are diffuse contaminants from population-scale sources, and both are removed effectively by reverse osmosis. The differences: pharmaceuticals are well-characterized chemicals with established toxicology profiles, while microplastics are physical particles whose health effects are still actively being studied. Pharmaceuticals have established laboratory detection methods; microplastics do not yet have an EPA-approved standard method.
How can I dispose of unused medication safely?
Use pharmacy take-back programs whenever possible — most major chains and many municipalities run them. The DEA hosts National Prescription Drug Take Back Day events twice yearly. For drugs that cannot be taken back, mix with coffee grounds or cat litter and dispose in regular trash rather than flushing. Only flush medications that appear on the FDA’s specific flush list (a short list of opioids and a few other controlled substances where diversion risk outweighs water-quality concern).
Check Your City
Pharmaceutical exposure is essentially universal among people drinking treated US tap water, but concentrations vary substantially based on source water, upstream wastewater discharges, and treatment technology. WaterVerge tracks the regulated contaminant data that drives utility compliance, and we update our coverage as the EPA advances pharmaceuticals through the CCL 6 → UCMR → regulatory determination pipeline.
Search your city to review your utility’s regulated contaminant data, violation history, and infrastructure details. If pharmaceutical exposure is a specific concern — most relevant for people with hypertension on multiple medications, pregnancies, immunocompromised households, and infant-formula preparation — an NSF/ANSI 401 certified point-of-use filter is the most direct mitigation available today.
Check your city's water
See if this contaminant has been detected in your local water supply.
Search your city →